RxDoctor Payments DataLook up a doctor →

Gautam Kedia, MD

Cardiovascular Disease · Chandler, AZNPI 1518179373

Payments from drug & device makers

$44,827in general payments, 2019–2025

Across 765 payments — averaging $58.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$27K
  • Boston Scientific$2K
  • Abbott$2K
  • Novartis$1K
  • Heartflow, Inc.$1K
  • Boehringer Ingelheim$912
  • plus $11K from 48 others

What the payments were for

  • Travel & lodging$1,4488%
  • Food & beverage$15,81487%
  • Education$4783%
  • Other$4022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,827 in reported general payments places this provider in the 85th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$1,107,964
Medicare patients
2,048
Services billed
12,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban411$579,412
XareltoRivaroxaban104$120,986
EntrestoSacubitril/Valsartan73$94,024
Repatha SureclickEvolocumab97$88,621
JardianceEmpagliflozin53$74,346
MultaqDronedarone Hcl30$51,652
VascepaIcosapent Ethyl17$17,900
Dabigatran EtexilateDabigatran Etexilate Mesylate64$15,146
Flecainide Acetate152$7,521
Losartan Potassium405$4,018
Atorvastatin Calcium390$3,779
Carvedilol358$3,525
Metoprolol Succinate230$3,034
Hydralazine Hcl176$2,665
Rosuvastatin Calcium259$2,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$601$579,412411 claims
Johnson & JohnsonXarelto$837$120,986104 claims
NovartisEntresto$1,083$94,02473 claims
Boehringer IngelheimJardiance$912$74,34653 claims
Sanofi-aventis U.S. LLCMultaq$290$51,65230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →